Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
INTRODUCTION: Urothelial carcinoma with squamous differentiation (UCS) is associated with increased resistance to chemotherapy, but outcomes associated with newer therapies approved in this space over the last 5 to 10 years are less well defined. We investigated clinical outcomes and molecular profiling of patients with UCS treated with an immune checkpoint inhibitor (ICI) and/or Enfortumab vedotin (EV).
PATIENTS AND METHODS: We undertook a retrospective analysis of UC patients treated with ICI and/or EV. Objective response rate (ORR), progression free survival (PFS) and overall survival (OS) were compared between pure UC (pUC) and UCS using X2 and log-rank tests, respectively. Prevalence of the most commonly detected somatic alterations were also compared between the 2 histologic subgroups.
RESULTS: A total of 160 patients (40 UCS, 120 pUC) were identified for this analysis. Among 151 patients treated with ICI (38 UCS, 113 pUC), UCS patients had a shorter mPFS (1.9 vs. 4.8 months, P < 0.01) and mOS (9.2 vs. 20.7 months, P < 0.01) compared to pUC. Among 37 patients treated with EV (12 UCS, 25 pUC), UCS patients had a lower ORR (17% vs. 70%, P < 0.01) and shorter mPFS (3.4 vs. 15.8 months, P < 0.01). UCS samples were enriched for CDKN2A, CDKN2B, PIK3CA, while pUC samples were enriched for ERBB2 alterations.
CONCLUSION: In this single-center retrospective analysis, patients with UCS had a distinct somatic genomic profile relative to patients with pUC. Patients with UCS also had inferior outcomes to ICIs and EV compared to patients with pUC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Clinical genitourinary cancer - 21(2023), 5 vom: 05. Okt., Seite e394-e404 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jindal, Tanya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibody drug conjugate |
|---|
| Anmerkungen: |
Date Completed 02.10.2023 Date Revised 02.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clgc.2023.05.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358180228 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358180228 | ||
| 003 | DE-627 | ||
| 005 | 20231226074208.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clgc.2023.05.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1193.xml |
| 035 | |a (DE-627)NLM358180228 | ||
| 035 | |a (NLM)37316414 | ||
| 035 | |a (PII)S1558-7673(23)00118-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jindal, Tanya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.10.2023 | ||
| 500 | |a Date Revised 02.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a INTRODUCTION: Urothelial carcinoma with squamous differentiation (UCS) is associated with increased resistance to chemotherapy, but outcomes associated with newer therapies approved in this space over the last 5 to 10 years are less well defined. We investigated clinical outcomes and molecular profiling of patients with UCS treated with an immune checkpoint inhibitor (ICI) and/or Enfortumab vedotin (EV) | ||
| 520 | |a PATIENTS AND METHODS: We undertook a retrospective analysis of UC patients treated with ICI and/or EV. Objective response rate (ORR), progression free survival (PFS) and overall survival (OS) were compared between pure UC (pUC) and UCS using X2 and log-rank tests, respectively. Prevalence of the most commonly detected somatic alterations were also compared between the 2 histologic subgroups | ||
| 520 | |a RESULTS: A total of 160 patients (40 UCS, 120 pUC) were identified for this analysis. Among 151 patients treated with ICI (38 UCS, 113 pUC), UCS patients had a shorter mPFS (1.9 vs. 4.8 months, P < 0.01) and mOS (9.2 vs. 20.7 months, P < 0.01) compared to pUC. Among 37 patients treated with EV (12 UCS, 25 pUC), UCS patients had a lower ORR (17% vs. 70%, P < 0.01) and shorter mPFS (3.4 vs. 15.8 months, P < 0.01). UCS samples were enriched for CDKN2A, CDKN2B, PIK3CA, while pUC samples were enriched for ERBB2 alterations | ||
| 520 | |a CONCLUSION: In this single-center retrospective analysis, patients with UCS had a distinct somatic genomic profile relative to patients with pUC. Patients with UCS also had inferior outcomes to ICIs and EV compared to patients with pUC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Antibody drug conjugate | |
| 650 | 4 | |a Genetic markers | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Urinary bladder neoplasms | |
| 650 | 7 | |a enfortumab vedotin |2 NLM | |
| 650 | 7 | |a DLE8519RWM |2 NLM | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 700 | 1 | |a Zhang, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Deshmukh, Prianka |e verfasserin |4 aut | |
| 700 | 1 | |a Reyes, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Vipul |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Xiaolin |e verfasserin |4 aut | |
| 700 | 1 | |a Maldonado, Edward |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Angelidakis, Austin |e verfasserin |4 aut | |
| 700 | 1 | |a Kwon, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Desai, Arpita |e verfasserin |4 aut | |
| 700 | 1 | |a Borno, Hala T |e verfasserin |4 aut | |
| 700 | 1 | |a Bose, Rohit |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Julian |e verfasserin |4 aut | |
| 700 | 1 | |a Carroll, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Maxwell |e verfasserin |4 aut | |
| 700 | 1 | |a Porten, Sima |e verfasserin |4 aut | |
| 700 | 1 | |a Aggarwal, Rahul |e verfasserin |4 aut | |
| 700 | 1 | |a Small, Eric J |e verfasserin |4 aut | |
| 700 | 1 | |a Fong, Lawrence |e verfasserin |4 aut | |
| 700 | 1 | |a Chou, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Friedlander, Terence |e verfasserin |4 aut | |
| 700 | 1 | |a de Kouchkovsky, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a Koshkin, Vadim S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical genitourinary cancer |d 2005 |g 21(2023), 5 vom: 05. Okt., Seite e394-e404 |w (DE-627)NLM160229936 |x 1938-0682 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2023 |g number:5 |g day:05 |g month:10 |g pages:e394-e404 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clgc.2023.05.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2023 |e 5 |b 05 |c 10 |h e394-e404 | ||